National Defense Medical Center

Other

Wellhead Biological Technology Corp.

National Defense Medical Center & Academia Sinica

National Defense Medical University

Lee, Sheau-long

Ann Chen

Shuk-Man Ka

Kuo-Feng Hua

Yu-Chieh Lee

Sheau-Long Lee

Kuo-Ping Chao

Wen-Liang Chang

Shih-Hsiung Wu

Chen-Wen Yao

Kuo-Yuan Hwa

Hao-Ai Shui

Hsu-Shan Huang

Shui-Tein Chen

An-Rong Lee

Wen-Hsin Huang

Shun-Min Yang

Chi-Hong Chu

Yulin Lam

Jia-Ming Chang

Yung-Jen Tsai

Chiao-Ying Chien

Chien-Yi Pai

Chao-Wen Cheng

Jenn-Han Chen

Wan-Han Hsu

The current invention is in the field of molecular biology/pharmacology and provides methods of using a pharmaceutical composition of 5-(2',4′-difluorophenyl)-salicylanilide derivatives and their ring-fused analogs for inhibiting, reducing, or treating chronic kidney disease or/and renal fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.

Method for ameliorating progression of renal fibrosis and treating renal fibrosis by 5-(2',4′-difluorophenyl)-salicylanilide derivatives

The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.

Tris DBA pharmaceutical composition and its use for treating autoimmune diseases

The present invention provides a lectin fromoras diagnostic reagents for IgA nephropathy. The present invention also provides a diagnostic kit for detecting Galactose-deficient IgA1 (Gd-IgA1), comprising RussiaSea-001 (also called as CGL) isolated fromor RussiaSea-002 (also called as MTL) isolated from. The present invention further provides a method for detecting Gd-IgA1 using RussiaSea-001 or RussiaSea-002.

Diagnostic kits and methods configured to rapidly and non-invasively determine physiologic levels of galactose-deficient IgA1 (Gd-IgA1) in the subject of IgA nephropathy

The present invention provides a method of inhibiting renal fibrosis in a subject in need thereof.

Use of ginsenoside M1 for inhibiting renal fibrosis

The present invention provides a method of treating a subject afflicted with IgA nephropathy (IgAN) comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.

Use of ginsenoside M1 for treating IgA nephropathy

The present invention provides a method of treating a subject afflicted with lupus nephritis comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.

Use of ginsenoside M1 for treating lupus nephritis

The preset invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of polyenylpyrrole derivatives of formula (I) or a pharmaceutically acceptable salt thereof.

Use of polyenylpyrrole derivatives for treating inflammation

The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage/lymphocyte infiltration in the kidney, etc.

Use of osthole for treating focal segmental glomerulosclerosis

The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Use of hydroxycinnamaldehyde glycoside derivatives for treating glomerulonephritis

The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Use of citral for treating focal segmental glomerulosclerosis

Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment.

Method for renal disease diagnosis using Rab23 as marker

The present invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of a composition comprising bamboo vinegar or the phenolic fraction thereof. The method for preparing the phenolic fraction is also provided.

Use of bamboo vinegar for treating inflammation

Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

[object Object]

The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.

Growing community of inventors

Taipei, Taiwan

Ann Chen